Fusion Pharmaceuticals to present interim data from Phase 1 trial of FPI-1434

Fusion Pharmaceuticals announced the presentation of interim data from the dose escalation portion of the Phase 1 trial of FPI-1434 in patients with solid tumors expressing IGF-1R. The data will be presented by Neeta Pandit-Taskar, M.D., of Memorial Sloan Kettering Cancer Center, tomorrow at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting and will include molecular imaging, safety and pharmacokinetics from two dosing regimens: one with FPI-1434 alone, and another in which a small dose of cold antibody is administered prior to each dose of FPI-1434. The poster presentation is available via the SNMMI Annual Meeting mobile application. “Antibody drug conjugates have shown tremendous success recently, driven in part by the benefits of using more potent payloads. We believe that the high potency of alpha emitters in place of conventional chemical toxins represents the evolution of the ADC field and is a significant and underexploited opportunity. While much is known about optimal dosing levels and paradigms for small molecule radiopharmaceuticals against well-known targets like PSMA, there is comparatively less experience for antibody-based alpha therapies in solid tumors. Consequently, in the Phase 1 study of FPI-1434, we undertook a stepwise dose exploration, in patients with various cancer types expressing IGF-1R, that included three stages: hot only regimen in a single ascending dose escalation; hot only regimen in a multiple ascending dose escalation; and cold/hot regimen in a multiple ascending dose escalation. Learnings from this multi-part study have taken us a step further towards unlocking the potential of antibody-based TATs as next-generation ADCs,” said Chief Executive Officer John Valliant, Ph.D.